Curamir Therapeutics, Inc.

Curamir Therapeutics, Inc. is a biotechnology startup based in the United States, founded in 2019 with a clear mission encapsulated in their slogan, "Finding RNA-targeted cures for cancer." The company leverages over a decade of innovative research and development on microRNA and cancer by Professor Jingfang Ju of Renaissance School of Medicine, Stony Brook University. Curamir focuses on developing transformative RNA-targeted life-changing oncology therapies, primarily through a technology platform with broad therapeutic potential. In their near-term initiatives, Curamir is directing its efforts towards developing microRNA (miRNA) mimics to target resistant cancer stem-like cells. These efforts are supported by their patented platform technologies, which have unique modifications of miRNA providing enhancement to stability, efficacy, and ease of delivery. The company has successfully secured a $10.00M Series A investment on 23 September 2019 from Delos Capital. Overall, Curamir Therapeutics, Inc. stands as a promising venture in the biotechnology sector, leveraging cutting-edge RNA-targeted therapeutic approaches to address the challenges of cancer treatment.